Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Advanced Medical Diagnostics SA to open 15 Tissue Differentiation Diagnostic Centres

Advanced Medical Diagnostics SA, a privately held company committed to providing innovative computer-aided solutions (HistoScanning™) that improve the diagnostic interpretation of ultrasound scans, today announced a collaboration with the BUND-DER-UROLOGEN for the opening of 15 Tissue Differentiation Diagnostic Centres.

18 Dec 2009

Study findings highlight the need to develop specific health policies to address social disparities

Racial and ethnic disparities in cancer survival are greatest for cancers that can be detected early and treated successfully, including breast and prostate cancer, according to a study by researchers at Columbia University's Mailman School of Public Health and Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Medical Center/NewYork-Presbyterian Hospital.

18 Dec 2009

Brachytherapy for lung cancer

A 58-year-old man who lives in Corona, Queens came to the emergency room of New York Hospital Queens (NYHQ) with extreme pain and tingling in his left arm. Although he did not realize it at the time, he had lung cancer. Recently, he made medical history as the first patient in the United States to be treated for lung cancer through the use of radioactive pellets placed directly in the tumor, and today his recovery is going well. Known as brachytherapy, this treatment approach is commonly used to treat prostate cancer.

18 Dec 2009

Discovery of common single-letter variant in SNP links parental origin to risk of T2D

Scientists at deCODE genetics, Inc. publish in the journal Nature the discovery of a version of a common single-letter variant in the sequence of the human genome (SNP) with a major impact on susceptibility to type 2 diabetes (T2D).

17 Dec 2009

Phase Forward’s InForm Global Trial Management solution standardized to support early-stage clinical trials

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced that Cancer Research UK’s Drug Development Office – the drug development arm of the world’s largest independent organization dedicated to cancer research – is standardizing on Phase Forward’s InForm™ Global Trial Management solution to support its diverse portfolio of early-stage clinical trials.

17 Dec 2009

Prostate cancer tests promised but not delivered

Men's Health Network calls on Congress to ensure that healthcare reform does not override the prostate cancer testing benefit currently required of insurance companies in 37 states.

16 Dec 2009

Discovery may yield new treatments for hormone-resistant prostate cancer

Patients with advanced prostate cancer are often treated with hormones, but when the tumours start growing again they have more and different blood vessels, reveals a thesis from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. This discovery paves the way for new treatments for hormone-resistant prostate cancer.

16 Dec 2009

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.

15 Dec 2009

Preventing tumours from making new blood vessels can also prevent spread of cancer

15 Dec 2009

Health experts discuss new treatment strategies for lung cancer at AACR-IASLC Joint Conference

In partnership with the International Association for the Study of Lung Cancer, the American Association for Cancer Research will host the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, which will bring together leaders from all over the world who share the goal of eradicating this form of cancer.

15 Dec 2009

New program to help maintain bone health in men with prostate cancer on ADT announced

Watson Pharmaceuticals, Inc. today announced a new program encouraging health professionals to help maintain the bone health of prostate cancer patients who are on long-term androgen deprivation therapy (ADT).

15 Dec 2009

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Algeta ASA, the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton.

14 Dec 2009

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Ipsen today announced the preliminary results of a phase I trial in metastatic breast cancer with BN83495, Ipsen’s lead and first-in-class orally available irreversible steroid sulfatase (STS) inhibitor.

14 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well.

11 Dec 2009

Eli Lilly provides financial guidance for 2010

At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

10 Dec 2009

Urodynamix Technologies reviews strategic alternatives for sale of company's assets

Urodynamix Technologies Ltd. today announces that its Board of Directors has initiated a process to review strategic alternatives including the sale of part of or all of the Company's assets.

10 Dec 2009

CPRIT awards $2 million grant to study prostate cancer

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded its initial grant for a First-Time, Tenure Track Faculty Member to the University of Texas Southwestern Medical Center in Dallas.

10 Dec 2009

Today's opinions and editorials

The language in our amendment is completely consistent with the Hyde Amendment, which in the 33 years since its passage has done nothing to inhibit private health insurers from offering abortion coverage. There is no reason to believe that a continuation of this policy would suddenly create undue hardship for the insurance industry — or for those who wish to use their private insurance to pay for an abortion (Rep. Bart Stupak, 12/8).

9 Dec 2009

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists.

9 Dec 2009

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Advanced Medical Diagnostics SA to open 15 Tissue Differentiation Diagnostic Centres

Study findings highlight the need to develop specific health policies to address social disparities

Brachytherapy for lung cancer

Discovery of common single-letter variant in SNP links parental origin to risk of T2D

Phase Forward’s InForm Global Trial Management solution standardized to support early-stage clinical trials

Prostate cancer tests promised but not delivered

Discovery may yield new treatments for hormone-resistant prostate cancer

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

Preventing tumours from making new blood vessels can also prevent spread of cancer

Health experts discuss new treatment strategies for lung cancer at AACR-IASLC Joint Conference

New program to help maintain bone health in men with prostate cancer on ADT announced

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Texas researchers identify new detection method for circulating tumor cells

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Eli Lilly provides financial guidance for 2010

Urodynamix Technologies reviews strategic alternatives for sale of company's assets

CPRIT awards $2 million grant to study prostate cancer

Today's opinions and editorials

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in